Supernus Pharmaceuticals
SUPN
223 hedge funds and large institutions have $1.45B invested in Supernus Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 80 increasing their positions, 76 reducing their positions, and 33 closing their positions.
616% more call options, than puts
Call options by funds: $6M | Put options by funds: $838K
5% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 76
0.09% more ownership
Funds ownership: 102.24% → 102.33% (+0.09%)
3% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 33
1% less funds holding
Funds holding: 226 → 223 (-3)
13% less capital invested
Capital invested by funds: $1.67B → $1.45B (-$216M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$15.5M |
| 2 |
EIP
Epoch Investment Partners
New York
|
+$10.5M |
| 3 |
MFIMFI
Mesirow Financial Investment Management - Fixed Income
Chicago,
Illinois
|
+$8.89M |
| 4 |
Millennium Management
New York
|
+$8.39M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$7.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$25.1M |
| 2 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$14M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$10.4M |
| 4 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$6.38M |
| 5 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
-$5.23M |
SUPN Hedge Fund Activity: Q3 2021 in Review
223 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q3 2021, worth a combined $1.45B — down 13% from $1.67B a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of SUPN and 32 opened new positions — a net loss of 1 holder — while 76 trimmed existing stakes and 80 added.
The largest buyer was Armistice Capital, adding an estimated $15.5M. The largest seller was Fidelity Investments, cutting an estimated $25.1M.
- 223 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q3 2021, down from 226 in Q2 2021.
- Funds reported $1.45B of Supernus Pharmaceuticals stock for Q3 2021, down 13% quarter-over-quarter.
- 32 funds opened new Supernus Pharmaceuticals positions in Q3 2021 and 33 closed out, a net change of -1 holder.
- The largest Supernus Pharmaceuticals buyer in Q3 2021 was Armistice Capital, an estimated $15.5M added.
- The largest Supernus Pharmaceuticals seller in Q3 2021 was Fidelity Investments, an estimated $25.1M sold.
Based on aggregated 13F filings for Q3 2021.